Olema Oncology to Participate at Upcoming Virtual Investor Conferences
SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will participate at the following upcoming virtual investor conferences:
Cowen 41st Annual Health Care ConferenceDate and Time: March 2, 2021 at 2:10 p.m. Eastern TimeSean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema, is scheduled to participate in a virtual breast cancer panel discussion.
33rd Annual ROTH Growth ConferenceDate and Time: March 15, 2021 at 5:00 p.m. Eastern TimeSean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema, is scheduled to participate in a virtual women’s health panel discussion.
About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
ContactsInvestor Contact:[email protected]
Media Contact:Sheryl Seapy, W2O[email protected]949-903-4750
Source: Olema Oncology
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Steelworkers back Canada holding the line on trade, call for a stronger response to protect Canadian jobs and industry
- FIA Celebrates Over Ninety Years of Supporting Motor Sport in the United States at the INDYCAR Freedom 250 Grand Prix of Washington D.C.
- Memecoin AI Agent Trading 2026: How MemeToro Could Redefine Automated Crypto Launches
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share